Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC 4.0Human Vaccines & Immunotherapeutics

Real-world safety outcomes of COVID-19 mRNA vaccine: A result from Korea post-marketing surveillance

6 affiliations
  1. 1Division of Infectious Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
  2. 2Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
  3. 3Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Republic of Korea
  4. 4Department of Otorhinolaryngology, Dankook University College of Medicine, Cheonan, Republic of Korea
  5. 5Pfizer Pharmaceutical Korea Ltd ., Seoul, Republic of Korea
  6. 6Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Abstract

The COVID-19 pandemic has caused a substantial global health burden, highlighting the need for post-authorization safety evaluation in real-world settings. BNT162b2 is a widely used mRNA COVID-19 vaccine, and, in addition to the original strain-based formulation, BA.1-, BA.4/5-, XBB.1.5-, and JN.1-adapted formulations were introduced sequentially. This study aimed to evaluate the real-world safety profile of the BNT162b2 product family using post-marketing surveillance data collected in Korea. Data collection was conducted from 50 sites. Solicited adverse events (AEs) were collected for 7 days, and unsolicited AEs for 28 days after vaccination. AEs occurring beyond Day 28 were also collected if reported during routine follow-up, without restriction on the collection period. Of 6,343 enrolled participants, 6,251 were included in the safety analysis set. Overall AEs were reported in 1,640 participants (26.2%) and adverse drug reactions (ADRs) in 1,610 participants (25.8%). Serious AEs occurred in 2 participants (<0.1%), and serious ADRs in 1 participant (<0.1%); no unexpected serious ADRs were identified. Solicited AEs were predominantly mild reactogenicity events, most commonly injection site pain, myalgia, fatigue, and headache. The overall safety profile of the BNT162b2 product family was generally manageable in this predominantly adult population, with very few serious ADRs and no unexpected serious ADRs identified. However, due to limited systematic capture of adverse events of special interest (AESIs) and underrepresentation of pediatric participants, AESI-related findings and pediatric safety conclusions should be interpreted with caution. These findings provide complementary real-world evidence regarding the safety of BNT162b2-adapted vaccines in Korea.

Related

  1. Durability and Safety of PULSTA Transcatheter Pulmonary Valve: Insights From Five-Year Nationwide Post-Marketing Surveillance Study in Korea
    Kyung-Jin Ahn, Gi Beom Kim, Sang Yun Lee +19
    Korean Circulation JournalPeer-reviewedCC BY-NC 4.0Full text1 citedCardiovascular medicinePMC
  2. Strengthening post-market COVID-19 vaccine safety surveillance and research: An interpretive description study from Kenya, South Africa, and Canada
    Anila Naz AliSher, Shabnam Shaik, Nellie Myburgh +15
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textImmunologyEpidemiology & public healthPLOSPMC
  3. Estimated COVID-19 outcomes averted by primary vaccine series among King County, Washington residents, February - September 2021: a retrospective modelling study of surveillance data.
    Kathryn M Lau, Katrin E Fabian, Meaghan S Fagalde +3
    BMC public healthPeer-reviewedCC BY-NC-NDFull textInfectious diseaseEurope PMCPMC
  4. Velaglucerase alfa for Gaucher disease in Japan: Long-term post-marketing surveillance data from a unique population with high rates of neuronopathic subtypes
    Miyako Hoshino, Kei Murayama, Hiroyuki Ida +2
    Molecular Genetics and Metabolism ReportsPeer-reviewedCC BY 4.0Full textHuman geneticsPMC
  5. Associations of school food environment characteristics (availability, pricing, and marketing) with adolescents’ dietary intake and anthropometric outcomes
    Mohammadhassan Rostami, Mina Babashahi
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
BibTeX
@article{han2026realworld,
  title = {{Real-world safety outcomes of COVID-19 mRNA vaccine: A result from Korea post-marketing surveillance}},
  author = {Sang Hoon Han and Jang Hee Hong and Sook in Jung and Ji-Hun Mo and Juwon Woo and Jacob Lee},
  journal = {Human Vaccines \& Immunotherapeutics},
  year = {2026},
  month = nov,
  doi = {10.1080/21645515.2026.2745407},
  url = {https://doi.org/10.1080/21645515.2026.2745407},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Real-world safety outcomes of COVID-19 mRNA vaccine: A result from Korea post-marketing surveillance
AU  - Sang Hoon Han
AU  - Jang Hee Hong
AU  - Sook in Jung
AU  - Ji-Hun Mo
AU  - Juwon Woo
AU  - Jacob Lee
PY  - 2026
DA  - 2026/11/06
JO  - Human Vaccines & Immunotherapeutics
DO  - 10.1080/21645515.2026.2745407
UR  - https://doi.org/10.1080/21645515.2026.2745407
AB  - The COVID-19 pandemic has caused a substantial global health burden, highlighting the need for post-authorization safety evaluation in real-world settings. BNT162b2 is a widely used mRNA COVID-19 vaccine, and, in addition to the original strain-based formulation, BA.1-, BA.4/5-, XBB.1.5-, and JN.1-adapted formulations were introduced sequentially. This study aimed to evaluate the real-world safety profile of the BNT162b2 product family using post-marketing surveillance data collected in Korea. Data collection was conducted from 50 sites. Solicited adverse events (AEs) were collected for 7 days, and unsolicited AEs for 28 days after vaccination. AEs occurring beyond Day 28 were also collected if reported during routine follow-up, without restriction on the collection period. Of 6,343 enrolled participants, 6,251 were included in the safety analysis set. Overall AEs were reported in 1,640 participants (26.2%) and adverse drug reactions (ADRs) in 1,610 participants (25.8%). Serious AEs occurred in 2 participants (<0.1%), and serious ADRs in 1 participant (<0.1%); no unexpected serious ADRs were identified. Solicited AEs were predominantly mild reactogenicity events, most commonly injection site pain, myalgia, fatigue, and headache. The overall safety profile of the BNT162b2 product family was generally manageable in this predominantly adult population, with very few serious ADRs and no unexpected serious ADRs identified. However, due to limited systematic capture of adverse events of special interest (AESIs) and underrepresentation of pediatric participants, AESI-related findings and pediatric safety conclusions should be interpreted with caution. These findings provide complementary real-world evidence regarding the safety of BNT162b2-adapted vaccines in Korea.
SN  - 2164-5515
SN  - 2164-554X
ER  -